文献速递妇科肿瘤

上皮性卵巢癌:精准医学时代治疗管理的演变

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
PubMed 文献 · CA Cancer J Clin · 2019-05-17

上皮性卵巢癌常晚期确诊,包含多种生物学与分子特性不同的亚型,且治疗可及性不一致。初次治疗主要依靠达到无残留病灶的减瘤手术和铂类化疗,对减瘤不理想及IV期患者加用抗血管生成药物;PARP抑制剂维持治疗已获批用于复发和BRCA1/BRCA2突变一线。当前研究聚焦深度分子与细胞图谱分析,以推进个体化精准医学。

要点

  • 初次治疗主要依靠达到无残留病灶的减瘤手术和铂类化疗。
  • 对减瘤不理想及IV期患者,加用抗血管生成药物。
  • PARP抑制剂维持治疗已获批用于复发和BRCA1/BRCA2突变一线。

核心结论

  • 改善这种侵袭性疾病生存需要获得适当的循证治疗。
  • 实现个体化精准医学需要优先开展创新治疗临床试验并完善预测性生物标志物。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • 卵巢癌是全球女性第二常见的妇科癌症死亡原因。
  • 疾病常晚期确诊,由多种生物学和分子特性不同的亚型组成,且治疗可及性不一致。
  • 初次治疗主要依靠达到无残留病灶的减瘤手术和铂类化疗。
  • 对减瘤不理想及IV期患者加用抗血管生成药物。
  • PARP抑制剂维持治疗已获批用于复发和BRCA1/BRCA2突变一线。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnosed late and composed of several subtypes with distinct biological and molecular properties (even within the same histological subtype), and there is inconsistency in availability of and access to treatment. Upfront treatment largely relies on debulking surgery to no residual disease and platinum-based chemotherapy, with the addition of antiangiogenic agents in patients who have suboptimally debulked and stage IV disease. Major improvement in maintenance therapy has been seen by incorporating inhibitors against poly (ADP-ribose) polymerase (PARP) molecules involved in the DNA damage-repair process, which have been approved in a recurrent setting and recently in a first-line setting among women with BRCA1/BRCA2 mutations. In recognizing the challenges facing the treatment of ovarian cancer, current investigations are enlaced with deep molecular and cellular profiling. To improve survival in this aggressive disease, access to appropriate evidence-based care is requisite. In concert, realizing individualized precision medicine will require prioritizing clinical trials of innovative treatments and refining predictive biomarkers that will enable selection of patients who would benefit from chemotherapy, targeted agents, or immunotherapy. Together, a coordinated and structured approach will accelerate significant clinical and academic advancements in ovarian cancer and meaningfully change the paradigm of care.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Lheureux S, Braunstein M, Oza AM, et al. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019. PMID: 31099893. doi:10.3322/caac.21559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。